simvastatin

This page shows the latest simvastatin news and features for those working in and with pharma, biotech and healthcare.

CETP inhibitor class finally dies as Merck abandons anacetrapib

ezetimibe) and sister product Vytorin (ezetimibe plus simvastatin) - into a blockbuster franchise.

Latest news

Merck & Co's anacetrapib data fails to generate much excitement

selling Zetia (ezetimibe) and Vytorin (ezetimibe/simvastatin) in this therapeutic area despite a small effect on cardiovascular outcomes.
FDA panel rejects cardiovascular outcomes claim for Vytorin

IMPROVE-IT involved 18, 000 high-risk patients with acute coronary syndromes (ACS) - including unstable angina and heart attacks - and compared Vytorin (ezetimibe and simvastatin) to simvastatin alone for their ability ... median seven-year follow-up
Merck hopes for another Keytruda with new immunotherapy deal

But Merck has been hit by the on-going erosion to its cardiovascular and cholesterol drugs Zetia (ezetimibe) and Vytorin (ezetimibe/simvastatin).
Relief as study finds no cardiovascular risk with Januvia

Overall pharma sales fell 2% on the back of declines for cholesterol drugs Zetia (ezetimibe) and Vytorin (ezetimibe/simvastatin) as well as immunotherapeutic Remicade (infliximab) which is facing biosimilar competition in
Merck's ezetimibe has 'modest' benefit when added to statins

The IMPROVE-IT trial was designed to compare the effects of Vytorin (simvastatin and ezetimibe) versus Zocor (simvastatin) on cardiovascular complications and death in 18, 000 post-ACS patients and got

More from news
Approximately 4 fully matching, plus 53 partially matching documents found.

Latest Intelligence

Rise of generic medicines in Portugal

Pedro Pita Barros, professor of economics and Nova School of Business and Economics, told PME: “ Patients have largely benefited from price decreases (for example, simvastatin dropped from above 50 for a ... Generics bestsellers in volume. Simvastatin.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Scientific Director: Great salary and bebefits

Account Manager – Med Comms – London: Salary TBC

Principal Medical Writer, Medical Communications, Relocate to Ca...: Excellent Salary

Editorial Team Leader or Scientific Director: £50, 000 - £55, 000 benefits

Senior Medical Writer: Great salary and benefits

Senior Account Manager – Med Comms – Kent: Salary TBC

Account Manager, Healthcare PR: £40, 000 – £42, 000 great benefits and bonuses

Head of Operations/ BUD, Healthcare PR, London – Excellent leade...: Excellent Package

Science writer, Healthcare Brand Communications, London, £45-50K...: £45-50K

Senior Medical Writer: Great salary and bebefits

Senior Account Manager / Account Director: Great salary and bebefits

Senior Account Manager or AD - Medical Communications: Salary TBC

Senior Medical Writer, Medical Communications, Relocate to Cardi...: Excellent Salary

Medical Writer - (London, Brighton or Copenhagen): Competitive

Editor > Senior Editor – Medical Education – London: Very competitive with excellent benefits

Senior / Principal Regulatory Writer – Home Working - UK or US: HIGHLEY COMPETATIVE SALARY, BONUS &BENEFITS

Senior Programme Executive: Salary TBC

Engagement Strategist, Healthcare Brand Communications, London, ...: Circa £60K

FREELANCE OPPORTUNITIES!!!!! Medical Education - Healthcare Adve...: EXCELLENT DAY RATES AVAILABLE

Subscribe to our email news alerts

PMHub

Add my company

Merrill Brink International

Merrill Brink International is a leading provider of life sciences, legal, financial, manufacturing and corporate language solutions for global companies....

Latest intelligence

Shaping healthcare: Bayer’s Lars Bruening talks about moving to the UK as the market works its way through a series of seismic changes...
No Voice, No Choice: Adelphi Research UK’s insights help to campaign for change in the Mental Health Act...
Pharma’s isolated islands of innovation: With service design and technology often failing the patient, why perspective on improving outcomes need to change...